Similarly, deletions in BNIP3 genes and epigenetic silencing of BNIP3 promoters are also extensively documented in a number of cancers, such as breast, gastric, pancreatic, liver, lung, and hematological malignancies [140,141,142,143,144] and are shown to be closely associated with chemoresistance and poor prognosis [141,145]. This evidence concerns the gene BNIP3 and cancer.